Last reviewed · How we verify
sitagliptin OR saxagliptin
Sitagliptin and saxagliptin are dipeptidyl peptidase-4 (DPP-4) inhibitors, which increase the levels of incretin hormones to enhance glucose-dependent insulin secretion.
Sitagliptin and saxagliptin are dipeptidyl peptidase-4 (DPP-4) inhibitors, which increase the levels of incretin hormones to enhance glucose-dependent insulin secretion. Used for Type 2 diabetes, Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
At a glance
| Generic name | sitagliptin OR saxagliptin |
|---|---|
| Also known as | januvia ® OR onglyza ® |
| Sponsor | University of Sao Paulo General Hospital |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
DPP-4 inhibitors like sitagliptin and saxagliptin work by blocking the action of DPP-4, an enzyme that breaks down incretin hormones. This leads to increased levels of incretin hormones, which in turn stimulate the release of insulin from the pancreas in a glucose-dependent manner. As a result, blood glucose levels are lowered, and the risk of hypoglycemia is reduced.
Approved indications
- Type 2 diabetes
- Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Headache
- Abdominal pain
- Vomiting
Key clinical trials
- The Role of Phosphodiesterase Inhibitors in Incretin Secretion (PHASE1)
- Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)
- Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes (PHASE3)
- Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes (PHASE4)
- Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation (NA)
- Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis (PHASE4)
- Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC (PHASE4)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sitagliptin OR saxagliptin CI brief — competitive landscape report
- sitagliptin OR saxagliptin updates RSS · CI watch RSS
- University of Sao Paulo General Hospital portfolio CI